Orbimed Advisors LLC bought a new stake in Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 140,428 shares of the company’s stock, valued at approximately $486,000. Orbimed Advisors LLC owned approximately 1.51% of Lakeshore Biopharma as of its most recent SEC filing.
Separately, Barclays PLC purchased a new stake in Lakeshore Biopharma in the 3rd quarter valued at approximately $169,000. 52.64% of the stock is currently owned by institutional investors.
Lakeshore Biopharma Stock Performance
NASDAQ LSB opened at $1.16 on Tuesday. The business’s 50 day moving average is $1.78 and its two-hundred day moving average is $2.35. Lakeshore Biopharma Co., Ltd. has a 12-month low of $1.10 and a 12-month high of $11.20. The company has a current ratio of 1.17, a quick ratio of 0.90 and a debt-to-equity ratio of 0.13.
Lakeshore Biopharma Profile
LakeShore Biopharma Co, Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People’s Republic of China and Other Countries or Regions.
Featured Articles
- Five stocks we like better than Lakeshore Biopharma
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 Stocks Plan +$130B in Buybacks: Why Markets Wanted Even More
- What Do S&P 500 Stocks Tell Investors About the Market?
- Lyft: Profitability Milestone and Buyback Fuel Investor Optimism
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- 3 Alternative Asset Managers Are Raising Dividends by 5% to 25%
Receive News & Ratings for Lakeshore Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakeshore Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
